202 related articles for article (PubMed ID: 18922908)
1. Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
Chaisuparat R; Hu J; Jham BC; Knight ZA; Shokat KM; Montaner S
Cancer Res; 2008 Oct; 68(20):8361-8. PubMed ID: 18922908
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene.
Martin D; Nguyen Q; Molinolo A; Gutkind JS
Oncogene; 2014 May; 33(18):2405-12. PubMed ID: 23708663
[TBL] [Abstract][Full Text] [Related]
3. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.
Park S; Chapuis N; Bardet V; Tamburini J; Gallay N; Willems L; Knight ZA; Shokat KM; Azar N; Viguié F; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Leukemia; 2008 Sep; 22(9):1698-706. PubMed ID: 18548104
[TBL] [Abstract][Full Text] [Related]
4. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.
Sodhi A; Chaisuparat R; Hu J; Ramsdell AK; Manning BD; Sausville EA; Sawai ET; Molinolo A; Gutkind JS; Montaner S
Cancer Cell; 2006 Aug; 10(2):133-43. PubMed ID: 16904612
[TBL] [Abstract][Full Text] [Related]
5. Akt/TSC/mTOR activation by the KSHV G protein-coupled receptor: emerging insights into the molecular oncogenesis and treatment of Kaposi's sarcoma.
Montaner S
Cell Cycle; 2007 Feb; 6(4):438-43. PubMed ID: 17329974
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
[TBL] [Abstract][Full Text] [Related]
7. Amplification of the angiogenic signal through the activation of the TSC/mTOR/HIF axis by the KSHV vGPCR in Kaposi's sarcoma.
Jham BC; Ma T; Hu J; Chaisuparat R; Friedman ER; Pandolfi PP; Schneider A; Sodhi A; Montaner S
PLoS One; 2011 Apr; 6(4):e19103. PubMed ID: 21559457
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
Chiarini F; Falà F; Tazzari PL; Ricci F; Astolfi A; Pession A; Pagliaro P; McCubrey JA; Martelli AM
Cancer Res; 2009 Apr; 69(8):3520-8. PubMed ID: 19351820
[TBL] [Abstract][Full Text] [Related]
9. PI3Kγ mediates kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis.
Martin D; Galisteo R; Molinolo AA; Wetzker R; Hirsch E; Gutkind JS
Cancer Cell; 2011 Jun; 19(6):805-13. PubMed ID: 21665152
[TBL] [Abstract][Full Text] [Related]
10. Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo.
Werzowa J; Koehrer S; Strommer S; Cejka D; Fuereder T; Zebedin E; Wacheck V
J Invest Dermatol; 2011 Feb; 131(2):495-503. PubMed ID: 21048785
[TBL] [Abstract][Full Text] [Related]
11. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
12. A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.
Zou ZQ; Zhang XH; Wang F; Shen QJ; Xu J; Zhang LN; Xing WH; Zhuo RJ; Li D
Int J Mol Med; 2009 Jul; 24(1):97-101. PubMed ID: 19513541
[TBL] [Abstract][Full Text] [Related]
13. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor.
Sodhi A; Montaner S; Patel V; Gómez-Román JJ; Li Y; Sausville EA; Sawai ET; Gutkind JS
Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4821-6. PubMed ID: 15047889
[TBL] [Abstract][Full Text] [Related]
14. Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma.
Schwab J; Antonescu C; Boland P; Healey J; Rosenberg A; Nielsen P; Iafrate J; Delaney T; Yoon S; Choy E; Harmon D; Raskin K; Yang C; Mankin H; Springfield D; Hornicek F; Duan Z
Anticancer Res; 2009 Jun; 29(6):1867-71. PubMed ID: 19528441
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
16. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates.
Mazzoletti M; Bortolin F; Brunelli L; Pastorelli R; Di Giandomenico S; Erba E; Ubezio P; Broggini M
Cancer Res; 2011 Jul; 71(13):4573-84. PubMed ID: 21602434
[TBL] [Abstract][Full Text] [Related]
17. Classic Kaposi's sarcoma treated with topical rapamycin.
Díaz-Ley B; Grillo E; Ríos-Buceta L; Paoli J; Moreno C; Vano-Galván S; Jaén-Olasolo P
Dermatol Ther; 2015; 28(1):40-3. PubMed ID: 25314592
[TBL] [Abstract][Full Text] [Related]
18. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME; Shokat KM
Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
Stallone G; Schena A; Infante B; Di Paolo S; Loverre A; Maggio G; Ranieri E; Gesualdo L; Schena FP; Grandaliano G
N Engl J Med; 2005 Mar; 352(13):1317-23. PubMed ID: 15800227
[TBL] [Abstract][Full Text] [Related]
20. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.
Fan QW; Cheng CK; Nicolaides TP; Hackett CS; Knight ZA; Shokat KM; Weiss WA
Cancer Res; 2007 Sep; 67(17):7960-5. PubMed ID: 17804702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]